TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, moves characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected.
The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an accelerant to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.
TapImmune’s technologies have broad applications in developing therapeutic and preventative vaccines. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens, among others.
Management believes that its cancer vaccine strategy is the only therapeutic approach that addresses the problem of “non-immunogenicity” of cancer. Since restoring the TAP protein directs the body’s immune system to specifically target cancerous cells without damaging healthy tissue, this therapy has a strong competitive advantage over other cancer therapies.
Let us hear your thoughts: TapImmune, Inc. Message Board